SCHEMBL27697246

SCHEMBL27697246

Cc1n[nH]c2cccc(C#N)c12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 1/20 0.65
CYP1A2 P05177 1/20 0.40
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.37
MAP2K4 P45985 1/20 0.37
MAPKAPK2 P49137 1/20 0.37
MAPK6 Q16659 1/20 0.37
LRRK2 Q5S007 3/20 0.37
AURKA O14965 2/20 0.36
AURKB Q96GD4 2/20 0.36
PLK4 O00444 1/20 0.36
CHEK1 O14757 1/20 0.36
CHUK O15111 1/20 0.36
ROCK2 O75116 1/20 0.36
CHEK2 O96017 1/20 0.36
INSR P06213 1/20 0.36
CDK1 P06493 1/20 0.36
CSF1R P07333 1/20 0.36
PIM1 P11309 1/20 0.36
FGFR1 P11362 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30548021 0.79 MAP2K1 (0.65) MAP2K1CYP1A2TSHRMAPK1LRRK2
SCHEMBL25249427 0.79 MAP2K1 (0.65) MAP2K1CYP1A2TSHRMAPK1LRRK2
SCHEMBL186113 0.79 MAP2K1 (1.00) MAP2K1LRRK2AURKAAURKBPLK4
SCHEMBL14631605 0.79 MAP2K1 (0.65) MAP2K1CYP1A2TSHRMAPK1MAP2K4
SCHEMBL19780200 0.75 MAP2K1 (0.37) MAP2K1LRRK2AURKAAURKBPLK4
SCHEMBL8404437 0.75 MAPK1 (0.54) MAP2K1CYP1A2TSHRMAPK1MAP2K4
SCHEMBL4416040 0.75 MAP2K1 (0.59) MAP2K1CYP1A2TSHRMAPK1LRRK2
SCHEMBL29950691 0.75 MAP2K1 (0.59) MAP2K1CYP1A2TSHRMAPK1LRRK2
SCHEMBL5530390 0.73 MAP2K1 (0.49) MAP2K1CYP1A2MAPK1GAA
SCHEMBL7737948 0.72 CYP1A2 (0.43) MAP2K1CYP1A2TSHRMAPK1MAP2K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101146796-A 3-(indazol-5-yl)-(1,2,4)triazine derivatives and related compounds as protein kinase inhibitors for the treatment of cancer SCHERING CORP (US) 2008-03-19 CN disclosed